Hoda Afsharirad

Tabriz University of Medical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Fariba Pourkarim

Tabriz University of Medical Sciences

Haleh Rezaei

Tabriz University of Medical Sciences

Marzieh Shahrabi

Tehran University of Medical Sciences

Mohammad Solduzian

Tabriz University of Medical Sciences

Elnaz Khani

Tabriz University of Medical Sciences

Taher Entezari‐Maleki

Tabriz University of Medical Sciences

Kazem Mehravani

Tabriz University of Medical Sciences

Naser Aslanabadi

Tabriz University of Medical Sciences

Elnaz Khani

Tabriz University of Medical Sciences

Cooperative Institutions

Tabriz University of Medical Sciences

Tehran University of Medical Sciences

Columbus Oncology and Hematology Associates

University of Florida

University of Tabriz

Shahid Beheshti University of Medical Sciences

Reckitt Benckiser (United States)

Shaheed Rajaei Cardiovascular Medical and Research Center

Cardiovascular Research Center

Biotechnology Research Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

All available clinical data on anakinra in COVID-19: an updated comprehensive review

Authorea (Authorea) (2024)

Marzieh Shahrabi Elnaz Khani Fariba Pourkarim Hoda Afsharirad Mohammad Solduzian

Background: Based on the investigations, cytokine-release syndrome (CRS) play a key role in the development of acute respiratory distress syndrome (ARDS) following SARS-CoV-2 infection. Anakinra can be effective in the management of CRS by inhibiting IL-1 from binding to the interleukin-1 receptors. We aimed to review the current clinical evidence regarding the therapeutic effects of anakinra in the management of ARDS in the context of the coronavirus disease 2019 (COVID-19). Methods: PubMed and google scholar databases were searched and all of the case reports, case series and RCTs were reviewed. Also, we searched www.clinicaltrial.gov database for ongoing clinical trials of anakinra. Results: Overall, 31 articles were found, and included 9 case report, 6 case-series and 11 RCTs. One of the reports of RCTs was not peer reviewed. Also, ten ongoing studies were found in the clinicaltrial.gov database searching. Conclusion: Four items have been shown to be important to achieve the optimal therapeutic effect of anakinra in patients withCOVID-19. These items include duration of treatment ≥ 10 days, doses of more than 100 mg, intravenous administration and early initiation of therapy. Also, the use of corticosteroids in combination with anakinra appears to improve clinical outcome compared to monotherapy with anakinra.

2019-20 coronavirus outbreak

10.22541/au.170666812.28371636/v1

Cite

Citations (0)

Current evidence on the use of anakinra in COVID-19

International Immunopharmacology (2022)

Elnaz Khani Marzieh Shahrabi Haleh Rezaei Fariba Pourkarim Hoda Afsharirad

Cytokine Storm

Cytokine Release Syndrome

10.1016/j.intimp.2022.109075

Cite

Citations (37)